Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Poolbeg Pharma CEO on POLB001 & GLP-1 trial plans - ICYMI
02:40am, Saturday, 04'th Oct 2025
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive about the company's interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June
Global Partners' Preferred Stock Has Become Less Attractive
11:59pm, Wednesday, 01'st Oct 2025
Global Partners preferred stock's 9.2% dividend remains safe, backed by strong business momentum and resilient cash flow. GLP operates 1,700 fueling stations, benefiting from economies of scale and a
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
05:14am, Wednesday, 01'st Oct 2025
Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 m
Why This Beaten-Down GLP-1 Stock Could Be a Steal
09:15am, Tuesday, 30'th Sep 2025
Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize o
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatm
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
09:15am, Monday, 29'th Sep 2025
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clin
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
10:15am, Sunday, 28'th Sep 2025
Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incr
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regai
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
04:21am, Friday, 26'th Sep 2025
Eli Lilly (LLY -3.77%) recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's (NVO -4.54%) oral version of Wegovy (semaglutide),
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
07:02am, Monday, 22'nd Sep 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancem
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
11:55am, Friday, 19'th Sep 2025
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
11:20am, Friday, 19'th Sep 2025
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy Kelowna, British Columbia – September 19, 2025 – TheNewswire - Lexaria Bioscience Corp. (Na
Eli Lilly's Oral GLP-1 Breakthrough Could Change Everything
03:25pm, Thursday, 18'th Sep 2025
Eli Lilly and Company NYSE: LLY has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, whi
Is Global Partners (GLP) Stock Outpacing Its Oils-Energy Peers This Year?
10:41am, Thursday, 18'th Sep 2025
Here is how Global Partners LP (GLP) and Siemens Energy AG Unsponsored ADR (SMNEY) have performed compared to their sector so far this year.
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:41am, Thursday, 18'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
